Formulary
Nintedanib: Indications, Dosing, Side Effects and Interactions
Nintedanib is a tyrosine protein kinase inhibitor.
MedNext Academy | 3 min read
Nintedanib: Indications, Dosing, Side Effects and Interactions
Nintedanib is a tyrosine protein kinase inhibitor.
Drug action
Nintedanib is a tyrosine protein kinase inhibitor.
Indications and dose
**Idiopathic pulmonary fibrosis (initiated by a specialist),Chronic fibrosing interstitial lung disease with a progressive phenotype (initiated by a specialist),Systemic sclerosis-associated interstitial lung disease (initiated by a specialist)**
- **Adult** (By Mouth): 150 mg twice daily, reduced if not tolerated to 100 mg twice daily, for dose adjustments due to side-effects, consult product literature.
**Non-small cell lung cancer (specialist use only)**
- **Adult** (By Mouth): Specialist indication - access specialist resources for dosing information.
Cautions
History or risk factors for QT prolongation; hypertension; impaired wound healing; increased risk of bleeding; patients at high risk of cardiovascular disease; previous abdominal surgery; recent history of hollow organ perforation; risk factors for aneurysm or artery dissection; theoretical increased risk of gastrointestinal perforation; theoretical increased risk of venous thromboembolism Cautions For Ofev Mild to moderate pulmonary hypertension
Contraindications
For Ofev Severe pulmonary hypertension
Side effects
Common or very common Abdominal pain; abscess; alopecia; appetite decreased; dehydration; diarrhoea; drug-induced liver injury; electrolyte imbalance; haemorrhage; headache; hyperbilirubinaemia; hypertension; mucositis; nausea; neutropenia; peripheral neuropathy; sepsis; skin reactions; stomatitis; thrombocytopenia; venous thromboembolism; vomiting; weight decreased Uncommon Gastrointestinal disorders; myocardial infarction; pancreatitis; renal impairment Frequency not known Aneurysm; artery dissection
Pregnancy
Manufacturer advises avoid-toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs .
Breast feeding
Manufacturer advises avoid-present in milk in animal studies.
Hepatic impairment
Manufacturer advises caution in mild impairment (risk of increased exposure); avoid in moderate to severe impairment (limited information available). Hepatic impairment For Ofev Dose adjustments Manufacturer advises dose reduction to 100 mg twice daily in mild impairment.
Renal impairment
Caution in severe impairment (no information available). M
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Nintedanib in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

